Higher proportions of Treg and proliferating CD8+ T cells were both associated with poor survival in malignancies lung cancer [41], suggesting that DC-CIK immunotherapy may play a role in enhancing the immune function of NSCLC patients. This evidence concerns the gene CD8A and non-small cell lung carcinoma.